Where is Merck & Co., Inc. (MRK) Headed According to the Street?

Merck & Co., Inc. (NYSE:MRK) is one of the best immunotherapy stocks to buy according to hedge funds. On February 13, Merck & Co., Inc. (NYSE:MRK) was upgraded to Buy from Hold by Deutsche Bank, with the firm raising the price target to $150 from $115 and telling investors that it believes the market is undervaluing the company because of Keytruda’s looming patent cliff. The firm’s analysis demonstrates a “clear path” for the company to navigate the transition effectively, adding that it believes Merck & C ...